CU20190105A7 - Combinación de un inhibidor de mcl-1 y un tratamiento de atención estándar para cáncer hematológico y composiciones farmacéuticas de esta - Google Patents

Combinación de un inhibidor de mcl-1 y un tratamiento de atención estándar para cáncer hematológico y composiciones farmacéuticas de esta

Info

Publication number
CU20190105A7
CU20190105A7 CU2019000105A CU20190105A CU20190105A7 CU 20190105 A7 CU20190105 A7 CU 20190105A7 CU 2019000105 A CU2019000105 A CU 2019000105A CU 20190105 A CU20190105 A CU 20190105A CU 20190105 A7 CU20190105 A7 CU 20190105A7
Authority
CU
Cuba
Prior art keywords
mcl
inhibitor
combination
pharmaceutical compositions
hematological cancer
Prior art date
Application number
CU2019000105A
Other languages
English (en)
Inventor
Olivier Geneste
Ana Leticia Maragno
Donia Moujalled
Giovanna Pomilio
Andrew Wei
Original Assignee
Servier Lab
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Servier Lab, Novartis Ag filed Critical Servier Lab
Publication of CU20190105A7 publication Critical patent/CU20190105A7/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Abstract

<p>Una combinación que comprende un inhibidor de Mcl-1 y un segundo agente anticanceroso, en la<br /> que el segundo agente anticanceroso se selecciona de antraciclinas, citarabina y agentes hipometilantes, y composiciones y usos de esta.</p>
CU2019000105A 2017-06-22 2018-06-21 Combinación de un inhibidor de mcl-1 y un tratamiento de atención estándar para cáncer hematológico y composiciones farmacéuticas de esta CU20190105A7 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762523389P 2017-06-22 2017-06-22
EP17189550 2017-09-06
PCT/EP2018/066551 WO2018234433A1 (en) 2017-06-22 2018-06-21 COMBINATION OF MCL-1 INHIBITOR AND CARE TREATMENT STANDARD FOR HEMATOLOGICAL CANCERS, USES AND ASSOCIATED PHARMACEUTICAL COMPOSITIONS

Publications (1)

Publication Number Publication Date
CU20190105A7 true CU20190105A7 (es) 2020-10-20

Family

ID=62631122

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2019000105A CU20190105A7 (es) 2017-06-22 2018-06-21 Combinación de un inhibidor de mcl-1 y un tratamiento de atención estándar para cáncer hematológico y composiciones farmacéuticas de esta

Country Status (25)

Country Link
US (1) US11466023B2 (es)
EP (1) EP3641775B1 (es)
JP (1) JP7186731B2 (es)
KR (1) KR20200018681A (es)
CN (2) CN111032050B (es)
AR (1) AR112202A1 (es)
AU (1) AU2018288520A1 (es)
BR (1) BR112019026959A2 (es)
CA (1) CA3068096C (es)
CL (1) CL2019003763A1 (es)
CO (1) CO2019014479A2 (es)
CU (1) CU20190105A7 (es)
EA (1) EA202090082A1 (es)
GE (1) GEP20227357B (es)
IL (1) IL271475B2 (es)
JO (1) JOP20190287A1 (es)
MA (1) MA49444A (es)
NI (1) NI201900128A (es)
PH (1) PH12019502789A1 (es)
SG (1) SG11201911891WA (es)
TW (1) TWI753178B (es)
UA (1) UA126920C2 (es)
UY (1) UY37777A (es)
WO (1) WO2018234433A1 (es)
ZA (1) ZA201908446B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202317200A (zh) 2021-06-11 2023-05-01 美商基利科學股份有限公司 Ｍｃｌ－１抑制劑與抗體藥物接合物之組合
US11957693B2 (en) 2021-06-11 2024-04-16 Gilead Sciences, Inc. Combination MCL-1 inhibitors with anti-cancer agents

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006508119A (ja) 2002-11-06 2006-03-09 ワイス 急性白血病および骨髄異形成症候群の治療のための組み合わせ療法
EP2358748B1 (en) 2008-12-09 2016-07-06 Dana-Farber Cancer Institute, Inc. Methods and compositions for specific modulation of mcl-1
US20130030237A1 (en) * 2010-04-15 2013-01-31 Charles Theuer Potentiation of anti-cancer activity through combination therapy with ber pathway inhibitors
CA2712747A1 (en) * 2010-08-11 2012-02-11 Universite De Montreal Combinatory cancer treatment
FR3015483B1 (fr) * 2013-12-23 2016-01-01 Servier Lab Nouveaux derives de thienopyrimidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
WO2015192014A1 (en) * 2014-06-13 2015-12-17 Calithera Biosciences, Inc. Combination therapy with glutaminase inhibitors
FR3037958B1 (fr) * 2015-06-23 2019-01-25 Les Laboratoires Servier Nouveaux derives d'hydroxy-acide, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3037957B1 (fr) * 2015-06-23 2019-01-25 Les Laboratoires Servier Nouveaux derives d'hydroxyester, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3037956B1 (fr) 2015-06-23 2017-08-04 Servier Lab Nouveaux derives d'acide amine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3037959B1 (fr) 2015-06-23 2017-08-04 Servier Lab Nouveaux derives bicycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3046792B1 (fr) 2016-01-19 2018-02-02 Les Laboratoires Servier Nouveaux derives d'ammonium, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
WO2018236904A1 (en) * 2017-06-19 2018-12-27 Surface Oncology, Inc. COMBINATION OF ANTI-CD47 ANTIBODIES AND CELL DEATH INDUCING AGENTS, AND USES THEREOF

Also Published As

Publication number Publication date
EP3641775A1 (en) 2020-04-29
CN117959451A (zh) 2024-05-03
AR112202A1 (es) 2019-10-02
IL271475A (en) 2020-01-30
JP7186731B2 (ja) 2022-12-09
JOP20190287A1 (ar) 2019-12-16
CO2019014479A2 (es) 2020-02-28
TWI753178B (zh) 2022-01-21
IL271475B1 (en) 2023-05-01
AU2018288520A1 (en) 2020-01-16
PH12019502789A1 (en) 2020-09-14
ZA201908446B (en) 2023-10-25
UY37777A (es) 2019-01-31
RU2020101626A (ru) 2021-07-22
GEP20227357B (en) 2022-02-25
SG11201911891WA (en) 2020-01-30
KR20200018681A (ko) 2020-02-19
TW201904579A (zh) 2019-02-01
MA49444A (fr) 2020-04-29
CA3068096C (en) 2022-10-04
US11466023B2 (en) 2022-10-11
BR112019026959A2 (pt) 2020-07-07
CL2019003763A1 (es) 2020-06-19
CN111032050A (zh) 2020-04-17
NI201900128A (es) 2020-03-30
US20200392151A1 (en) 2020-12-17
CA3068096A1 (en) 2018-12-27
EA202090082A1 (ru) 2020-05-22
EP3641775B1 (en) 2023-12-06
RU2020101626A3 (es) 2021-10-05
UA126920C2 (uk) 2023-02-22
CN111032050B (zh) 2024-01-19
JP2020524681A (ja) 2020-08-20
IL271475B2 (en) 2023-09-01
WO2018234433A1 (en) 2018-12-27

Similar Documents

Publication Publication Date Title
SV2018005778A (es) Derivados aromaticos de sulfonamida
SV2017005461A (es) Benzamidas sustituidas con 1,3-tiazol-2-ilo
CL2020001312A1 (es) Composiciones de cannabidiol y usos de las mismas. (divisional solicitud 201803425).
UY37952A (es) Formulaciones de un inhibidor de la quinasa trk macrocíclica
BR112018008601A2 (pt) composições compreendendo o canabidiol e segundos agentes terapêuticos para o tratamento de câncer
CL2017002214A1 (es) Formulación de combinación de tesofensina y betabloqueante
CL2019003572A1 (es) Combinaciones de brimonidina de dosis baja y usos de las mismas.
NI201900128A (es) Combinación de un inhibidor de mcl-1 y un tratamiento de atención estándar para cáncer hematológico, usos y composiciones farmacéuticas de esta
CO7131368A2 (es) (r)-nifuratel, su uso para el tratamiento de infecciones y síntesis de (r) y (s)-nifuratel
UY37342A (es) Combinación de un inhibidor de bcl-2 y un inhibidor de mcl1, usos y composiciones farmacéuticas de éstos
BR112018002520A2 (pt) Agonistas de tlr4 e composições dos mesmos e seuuso no tratamento de câncer
UY37560A (es) Combinación de un inhibidor de mcl-1 y un compuesto taxano, usos y composiciones farmacéuticas de ésta
CL2019002514A1 (es) Composiciones cosméticas para el cuidado de la piel.
BR112021000279A8 (pt) formulações de redução de tumor e métodos de uso das mesmas
ECSP19006687A (es) Combinación de un inhibidor de bcl-2 y un inhibidor de mcl-1, usos y composiciones farmacéuticas de éstos
BR112019000706A2 (pt) agente de estímulo do receptor 1b de 5-hidroxitriptamina para reparo de pele e/ou cabelo
CO2017001076A2 (es) Composiciones farmacéuticas antihiperalgésicas, antialodínicas y antiinflamatorias que contienen pregabalina y meloxicam
BR112018067453A2 (pt) combinações de glicoalcaloide e vários usos da mesma
ECSP19000169A (es) Formulaciones inyectables fisiológicamente balanceadas de fosnetupitant
CL2019003288A1 (es) Una combinación farmacéutica para el tratamiento de un cáncer.
CO2019007261A2 (es) Combinación de un inhibidor de mcl-1 y un compuesto taxano, usos y composiciones farmacéuticas de ésta
AR119334A1 (es) Inhibidores de la traducción y sus usos
UY37316A (es) Dispersión sólida farmacéutica de un inhibidor de bcl-2, composiciones farmacéuticas de ésta, y usos para el tratamiento de cáncer
MX2020004731A (es) Terapias de combinacion de inhibidor ezh2.
CU20180127A7 (es) Composiciones inmunogénicas de chagas